<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01115972</url>
  </required_header>
  <id_info>
    <org_study_id>1585-CL-0009</org_study_id>
    <nct_id>NCT01115972</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers</brief_title>
  <official_title>ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Valsartan -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the effect of ASP1585 on pharmacokinetics of valsartan in 2x2
      crossover method
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of valsartan</measure>
    <time_frame>for 48 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by AE, vital signs 12-lead ECG and lab tests</measure>
    <time_frame>for 5 days after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of Valsartan</condition>
  <arm_group>
    <arm_group_label>single-add first group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration first, then concomitant administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combi-add first group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concomitant administration first, then single administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1585</intervention_name>
    <description>oral</description>
    <arm_group_label>single-add first group</arm_group_label>
    <arm_group_label>combi-add first group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
    <description>oral</description>
    <arm_group_label>single-add first group</arm_group_label>
    <arm_group_label>combi-add first group</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: =&lt;50.0kg, &lt;80.0kg

          -  Body mass index: =&lt;17.6, &lt;26.4

          -  Healthy as judged by investigator or caregiver from subjective and objective symptoms
             and physical examination data

        Exclusion Criteria:

          -  Attending another clinical trial within 120 days before the study

          -  Blood donation within 90 days (400ml) or 30 days (200ml) before the study

          -  Receiving any drugs within 7 days before the study

          -  History of allergy to drugs

          -  Having GI disorders

          -  History or complication of liver diseases

          -  History or complication of heart disease

          -  History or complication of respiratory diseases

          -  History or complication of renal diseases

          -  History or complication of cerebrovascular diseases
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <last_update_submitted>May 26, 2010</last_update_submitted>
  <last_update_submitted_qc>May 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Astellas Pharma, Inc</organization>
  </responsible_party>
  <keyword>ASP1585</keyword>
  <keyword>Drug-drug interaction</keyword>
  <keyword>valsartan</keyword>
  <keyword>Healthy volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

